Ronald A Depinho

US Patent:

20130040853, Feb 14, 2013

Filed:

Jan 21, 2011

Appl. No.:

13/521882

Inventors:

Lynda Chin - Houston TX, US
Timothy P. Heffernan - Sugar Land TX, US
Ronald A. DePinho - Houston TX, US

Assignee:

Dana-Farber Cancer Institute Inc. - Boston MA

International Classification:

C40B 30/06

US Classification:

506 10

Abstract:

The present invention relates to a context-specific forward genetic screen designed to systematically assign relative weight of biological evidence to a library of high-probability driver genetic elements in a genetically defined cancer-sensitized model system whose constellation of engineered mutations reflects a particular clinically relevant genetic subclass of a given tumor type. The screen may be formed in vivo or ex vivo. The screen allows for the formulation of clinical path hypotheses for targeting driver genetic elements and, in parallel, the rapid functional validation of the role of the driver genetic element(s) in the cancer. In this manner, the context-specific genetic screen can systematically assign the biological relevance of a library of genetic elements to a clinically-definable genetic and disease context, as well as inform combinations of drugs in the clinic such one uses one drug that targets the newly discovered genetic element or its protein and another drug that targets those genetic elements or its associated proteins which have been engineered into the primary cell model.

US Patent:

20130072392, Mar 21, 2013

Filed:

May 17, 2012

Appl. No.:

13/473969

Inventors:

Ronald A. DePinho - Houston TX, US
Kenneth C. Anderson - Wellesley MA, US
Ruben D. Carrasco - Brookline MA, US
Giovanni Tonon - Cernusco Sul Naviglio, IT
Cameron Brennan - Haworth NJ, US
Lynda Chin - Houston TX, US

Assignee:

Board of Trustees of the University of Arkansas - Little Rock AR
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C40B 30/06
C12Q 1/68
G01N 33/574

US Classification:

506 9, 435 613, 435 611, 435 612, 435 792, 435 71, 435 74, 435 723

Abstract:

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer.

US Patent:

20140011748, Jan 9, 2014

Filed:

Jan 19, 2012

Appl. No.:

13/980522

Inventors:

Lynda Chin - Houston TX, US
Ronald A. Depinho - Houston TX, US
Giulio Draetta - Winchester MA, US
Timothy P. Heffernan - Sugar Land TX, US

Assignee:

DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

International Classification:

G01N 33/68

US Classification:

514 193, 435 612, 506 9, 435 71, 514406, 514367, 514369

Abstract:

This present invention provides methods of treating of accessing/monitoring the responsiveness of a cancer cell to JNK inhibitor therapy.

US Patent:

20180147219, May 31, 2018

Filed:

Mar 9, 2016

Appl. No.:

15/557288

Inventors:

- Austin TX, US
David S. MAXWELL - Pearland TX, US
William G. BORNMANN - Missouri City TX, US
Yu-Hsi LIN - Houston TX, US
Zhenghong PENG - Missouri City TX, US
Duoli SUN - Houston TX, US
Nikunj SATANI - Houston TX, US
M. Emilia DI FRANCESCO - Houston TX, US
Ronald A. DEPINHO - Houston TX, US
Barbara CZAKO - Houston TX, US
Federica PISANESCHI - Houston TX, US

International Classification:

A61K 31/675
C07F 9/59
C07F 9/572
A61P 35/00
C07F 9/553
A61K 45/06

Abstract:

Provided herein are compounds of the formula (I) wherein the variables R, R, R, R, X, X, Y, and Aare as defined herein. Such compounds may be used, for example, for the inhibition of enolase enzymes, including preferential inhibition of one isoenzyme of over one or more of the other isoenzymes. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.

US Patent:

20170340736, Nov 30, 2017

Filed:

May 25, 2017

Appl. No.:

15/605597

Inventors:

- Boston MA, US
Ronald A. DePinho - Houston TX, US
Ralph Weissleder - Peabody MA, US

International Classification:

A61K 41/00
A61K 35/34
A61K 47/54
C07D 295/088
C07C 279/08
C07C 217/18
A61N 5/06
A61K 45/06
A61K 35/44
A61K 35/36
A61K 35/35
A61K 35/32
A61K 35/30
A61K 31/5375
A61K 31/495
A61K 31/4453
A61K 31/40
A61K 31/155
A61K 31/137
C12N 9/00
C07C 2601/14

Abstract:

Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.

US Patent:

20170299594, Oct 19, 2017

Filed:

Oct 28, 2016

Appl. No.:

15/337966

Inventors:

Ronald A. Depinho - Houston TX, US
Zhihu Ding - Brookline MA, US
Lynda Chin - Houston TX, US

International Classification:

G01N 33/574
C12N 15/85
C07K 14/47
G01N 33/50
A01K 67/027
C12N 9/16
C12Q 1/68

Abstract:

The present invention provides methods of detecting cancer using biomarkers.

US Patent:

20160363596, Dec 15, 2016

Filed:

Aug 26, 2016

Appl. No.:

15/248474

Inventors:

Ronald A. Depinho - Houston TX, US
Zhihu Ding - Brookline MA, US
Chang-Jiun Wu - Houston TX, US
Lynda Chin - Houston TX, US

Assignee:

DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

International Classification:

G01N 33/574
A01K 67/027
G01N 33/50
C12Q 1/68

Abstract:

The present invention provides a set of DETERMINANTS (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use.

US Patent:

20150093365, Apr 2, 2015

Filed:

Mar 14, 2013

Appl. No.:

14/395210

Inventors:

- Boston MA, US
Sarit S. Agasti - Cambridge MA, US
Ronald A. DePinho - Houston TX, US
Ralph Weissleder - Peabody MA, US

International Classification:

A61K 41/00
A61K 47/48
A61K 35/36
A61K 45/06
A61K 35/44
A61K 35/34
A61K 35/12
A61K 35/32
A61K 35/30
A61K 31/155
A61K 31/40
A61K 31/4453
A61K 31/495
A61K 31/5375
A61N 5/06
A61K 31/137

US Classification:

424 9321, 564317, 514648, 564237, 514634, 548575, 514428, 546232, 514331, 544398, 51425212, 544167, 5142392, 548562, 514427, 4351731, 604 20

Abstract:

Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.